TSE:4587
TSE:4587Biotechs

How Investors May Respond To PeptiDream (TSE:4587) Expanding RNAi Delivery And Advancing Oral IL-17 Autoimmune Program

In December 2025, PeptiDream announced it had reached a preclinical development milestone with Alnylam in their siRNA delivery collaboration, and separately advanced its second oral peptide program, a dual IL-17A/IL-17F macrocyclic inhibitor for autoimmune diseases, into its clinical development portfolio. Together, these updates highlight the breadth of PeptiDream’s PDPS® platform, extending into extrahepatic RNAi delivery and potentially oral alternatives to injectable IL-17...
TSE:6874
TSE:6874Electronic

Top Asian Dividend Stocks To Consider In December 2025

As the Bank of Japan raises interest rates to levels not seen in decades and China's economic growth remains tepid, investors are closely monitoring the Asian markets for opportunities. In this environment, dividend stocks can offer a compelling option for those seeking steady income, as they often provide regular payouts that can help offset market volatility.